ArticlePloS one2025
Calcium scoring during 18F-FDG PET/CT in cancer indications: Improving cardiovascular risk stratification and prevention.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidental Detection of Coronary Artery Calcification in Women Undergoing Cancer Screening or Treatment.Current atherosclerosis reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCoronary artery calcium (CAC) can be assessed on 18F-FDG PET/CT in oncology patients. We evaluated the proportion of oncology patients referred for PET/CT imaging in whom systematic CAC scoring could reclassify cardiovascular (CV) risk and modify primary cardiovascular disease (CVD) prevention strategies. MATERIALS AND
methodsThis prospective study included 190 cancer patients undergoing 18F-FDG PET/CT in oncological indications at our institution between June and July 2024. Data on CV risk factors, personal/family CVD history, and current treatments were collected. CAC scores were assessed visually and automatically on CT scans. Patients' CV risk was reclassified according to CAC scores and compared with their current lipid-lowering therapy (LLT) and cardiology follow-up.
resultsA total of 190 subjects were analyzed (mean age 65 ± 13 years, 64% female, mean Framingham Risk Score 17.2 ± 9.2%). Patients were categorized as follows according to CAC: 24.7% (N = 47) no CAC, 36.8% (N = 70) mild, 21.6% (N = 41) moderate, and 16.8% (N = 32) severe CAC. Among them, 56.3% (N = 107) had a previous consultation with a cardiologist, 30.0% (N = 57) were on LLT, and 6.8% (N = 13) had a history of CVD. Based on CAC scoring, 43% (N = 81) could be reclassified in a different CVD risk category and 49% (N = 93) required changes in primary CVD prevention through LLT adjustments or initiating follow-up for high risk of CVD.
conclusionSystematic CAC assessment on PET/CT imaging could enhance CV risk stratification and prevention in oncology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.